Eli Lilly vs. Humanwell Pharmaceutical: Voluntary Dismissal in Lasmiditan Patent Dispute

Case Overview

The Parties

The Patent at Issue

The patent at issue, **U.S. Patent No. US11053214B2** (application number US16/467208), covers proprietary formulation or compound claims associated with lasmiditan — the active pharmaceutical ingredient in REYVOW®. Lasmiditan operates by selectively targeting the 5-HT1F receptor, offering migraine relief without vasoconstriction, a key differentiator from older triptan-class drugs.

• • US11053214B2 — Covers proprietary formulation or compound claims associated with lasmiditan.

Litigation Timeline & Procedural History

The case proceeded at an unusually rapid pace. Filed on March 21, 2025, and closed on July 7, 2025, the 108-day lifecycle suggests the litigation was resolved — or strategically withdrawn — well before any substantive motion practice, claim construction proceedings, or trial preparation could meaningfully advance.

The case was assigned to Chief Judge Stephen R. Clark of the Eastern District of Missouri, a jurist with a substantial federal civil docket. Venue selection in Missouri’s Eastern District, rather than Lilly’s home jurisdiction of Indiana or a high-volume patent district like Delaware, may reflect strategic considerations related to defendant’s registered presence or counsel availability.

No claim construction hearing, summary judgment ruling, or trial record is publicly indicated within this timeframe, reinforcing that the dismissal preceded all substantive adjudication.

Legal Representation

• • Plaintiff (Lilly): Attorney Stacey R. Gilman of Berkowitz Oliver LLP (Kansas City)
• • Defendant (Humanwell): Attorney Britton Laurence St. Onge of Polsinelli PC (St. Louis)

Both firms are established Missouri-region litigation practices, reflecting deliberate venue strategy by Lilly in selecting Eastern District of Missouri.

The Verdict & Legal Analysis

Outcome

On July 7, 2025, plaintiffs Eli Lilly & Company and co-plaintiff CoLucid Pharmaceuticals, Inc. filed a notice of voluntary dismissal without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). No damages were awarded. No injunctive relief was granted or denied. The case was terminated without any adjudication on the merits.

Critically, dismissal without prejudice means Lilly retains the full legal right to refile this exact infringement claim against Humanwell at any future date, subject to applicable statutes of limitations and procedural rules.

Verdict Cause Analysis

Because the dismissal occurred under Rule 41(a)(1)(A)(i) — a unilateral notice of dismissal filed before the defendant serves an answer or a motion for summary judgment — no court order was required, and no judicial findings were made regarding patent validity, infringement, or claim construction. The record contains no publicly disclosed claim construction rulings, expert reports, or dispositive motions.

The absence of substantive legal reasoning in the termination record is itself analytically significant. Possible strategic explanations include:

• • Settlement or licensing agreement: Parties may have reached a confidential licensing arrangement or covenant not to sue, rendering continued litigation unnecessary.
• • ANDA withdrawal or amendment: Humanwell may have amended its regulatory filing in a manner that mooted Lilly’s infringement theory.
• • Litigation timing strategy: Lilly may have determined that refiling in a different venue or at a more tactically advantageous time better serves its exclusivity protection goals.
• • Patent portfolio realignment: With multiple patents potentially covering lasmiditan across Lilly’s portfolio, a decision to enforce different claims or patents could prompt withdrawal of this specific action.

Legal Significance

The use of Rule 41(a)(1)(A)(i) is notable for its procedural efficiency — it requires no court involvement and leaves no adverse precedent. For patent practitioners, this mechanism represents one of the cleanest exits available to a plaintiff in early-stage litigation. However, defendants should note that the “two-dismissal rule” under Rule 41(a)(1)(B) could convert a subsequent dismissal to one with prejudice if Lilly refiles and dismisses again in federal court on the same claim.

Strategic Takeaways

For Patent Holders:
A voluntary dismissal without prejudice preserves optionality. Lilly’s exit strategy maintains litigation leverage — Humanwell cannot assume freedom to operate simply because this case closed. Pharmaceutical plaintiffs routinely use this approach when settlement negotiations are ongoing or regulatory developments shift the litigation calculus.

For Accused Infringers:
Generic manufacturers in Humanwell’s position should not interpret a Rule 41 dismissal as patent clearance. Absent a formal covenant not to sue or license agreement, the patent holder retains all enforcement rights. Humanwell’s legal team should conduct ongoing freedom-to-operate analysis relative to US11053214B2 and any continuation patents in Lilly’s lasmiditan portfolio.

For R&D Teams:
Product developers working on 5-HT1F receptor agonists or lasmiditan-adjacent compounds should treat this dismissal as a signal to maintain rigorous FTO (freedom-to-operate) monitoring. Lilly’s willingness to litigate — even if briefly — establishes an enforcement posture that should inform design decisions and patent clearance workflows.